Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Aaron T. Gerds, Ruben Mesa, John M. Burke, Michael R. Grunwald, Brady L. Stein, Peg Squier, Jingbo Yu, J. E. Hamer-Maansson, Stephen T. Oh

Blood (2024) 143 (16): 1646–1655.

https://doi.org/10.1182/blood.2023020232

Published: 2024

Includes: Supplemental data

Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa

Blood (2022) 140 (Supplement 1): 6810–6812.

https://doi.org/10.1182/blood-2022-158144

Published: 2022

Journal Articles

Direct and Indirect Costs of Patients with Myeloproliferative Neoplasm Diseases

Jingbo Yu, Michelle Jerry, James Nelson, Taylor Marlin, Evan Braunstein, Nicole Princic

Blood (2022) 140 (Supplement 1): 5268–5269.

https://doi.org/10.1182/blood-2022-166758

Published: 2022

Journal Articles

Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices

Srdan Verstovsek, Jingbo Yu, Emily Bland, Tammy Schuler, Thomas Cordaro, Evan Braunstein

Blood (2022) 140 (Supplement 1): 8131–8132.

https://doi.org/10.1182/blood-2022-169426

Published: 2022

Journal Articles

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Roger M. Lyons, Kathleen M. Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum, Ira Zackon, Jingbo Yu

Blood (2022) 140 (Supplement 1): 13310–13311.

https://doi.org/10.1182/blood-2022-163416

Published: 2022

Journal Articles

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Aaron T. Gerds, Ruben A. Mesa, John M. Burke, Michael R. Grunwald, Brady Lee Stein, Robyn Scherber, Jingbo Yu, J.E. Hamer-Maansson, Stephen Oh

Blood (2021) 138 (Supplement 1): 239.

https://doi.org/10.1182/blood-2021-148509

Published: 2021

Journal Articles

Disability Associated with Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Betty K. Hamilton, Paul Williams, Giulio Flore, John Galvin, James Turnbull, Jingbo Yu

Blood (2021) 138 (Supplement 1): 4060.

https://doi.org/10.1182/blood-2021-153201

Published: 2021

Journal Articles

Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States

Srdan Verstovsek, MD PhD, Jingbo Yu, MD PhD, Robyn M. Scherber, MD, Shivani Pandya, MS, Christopher Dieyi, MPH, Chien-Cheng Chen, MS, Shreekant Parasuraman, BPharm, PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-141090

Published: 2020

Journal Articles

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

Brady L. Stein, MD MHSc, Kamal Patel, MD, Robyn M. Scherber, MD, Jingbo Yu, MD PhD, Dilan Paranagama, PhD, Carole B. Miller, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137144

Published: 2020

Journal Articles

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-141370

Published: 2020

Journal Articles

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Naveen Pemmaraju, MD, Aaron T. Gerds, MDMS, Jingbo Yu, MD PhD, Shreekant Parasuraman, BPharm, PhD, Anne Shah, Ann Xi, PharmD, Shambhavi Kumar, MS, Robyn M. Scherber, MD, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-141333

Published: 2020

Journal Articles

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Srdan Verstovsek, MD PhD, Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, MD PhD, Anne Shah, Shambhavi Kumar, MS, Ann Xi, PharmD, Claire Harrison, DM, FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140820

Published: 2020

Journal Articles

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Paranagama, PhD, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 5385.

https://doi.org/10.1182/blood-2019-123833

Published: 2019

Journal Articles

Disease Progression, Hospital Readmissions, and Clinical Outcomes of Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Chart Review

Jingbo Yu, PhD, Becky Hanna, Dilan Paranagama, PhD, Jackson Tang, Ahmad Naim, MD, John P Galvin, MDMS,MPH

Blood (2019) 134 (Supplement_1): 1994.

https://doi.org/10.1182/blood-2019-127492

Published: 2019

Journal Articles

Elevated White Blood Cell Levels and Thrombotic Events in Patients with Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data

Shreekant Parasuraman, BPharm, PhD, Jingbo Yu, PhD, Dilan Chamikara Paranagama, PhD, Sulena Shrestha, MPH, Li Wang, PhD, Onur Baser, PhD, Robyn Marie Scherber, MD MPH

Blood (2018) 132 (Supplement 1): 1758.

https://doi.org/10.1182/blood-2018-99-118451

Published: 2018

Journal Articles

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Srdan Verstovsek, MD PhD, Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Chamikara Paranagama, PhD, Jill Kaufman, Jessica Chung, PhD MPH, Michael R. Grunwald, MD, Philomena Colucci, DO, MS, Ruben A. Mesa, MD FACP

Blood (2018) 132 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2018-99-115294

Published: 2018

Journal Articles

Impact of Myeloproliferative Neoplasms on Patients' Employment and Income: Findings from the Living with MPN Survey

Simon Condliffe, PhD MS, Jingbo Yu, PhD, Dilan Chamikara Paranagama, PhD, Shreekant Parasuraman, BPharm, PhD

Blood (2018) 132 (Supplement 1): 2250.

https://doi.org/10.1182/blood-2018-99-115345

Published: 2018

Journal Articles

Real-World Patterns of First-Line Hydroxyurea Treatment Among Patients with Essential Thrombocythemia in US Community Oncology Practices

Jingbo Yu, PhD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Smitha Sivaraman, PhD, Pavel Atanasov, Becky Hanna, Jackson Tang, Shreekant V. Parasuraman, BPharm, PhD

Blood (2017) 130 (Supplement 1): 4203.

https://doi.org/10.1182/blood.V130.Suppl_1.4203.4203

Published: 2017

Journal Articles

Characteristics of 809 Patients with Essential Thrombocythemia in Real-World Clinical Practice: A Chart Review Study in the United States

Jingbo Yu, PhD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Smitha Sivaraman, PhD, Pavel Atanasov, Becky Hanna, Jackson Tang, Shreekant V. Parasuraman, BPharm, PhD

Blood (2017) 130 (Supplement 1): 1636.

https://doi.org/10.1182/blood.V130.Suppl_1.1636.1636

Published: 2017

Journal Articles

Role of Symptom Burden in Disability Leave Among Patients with Myeloproliferative Neoplasms (MPNs): Findings from the Living with MPN Patient Survey

Jingbo Yu, PhD, Dilan Chamikara Paranagama, PhD, Holly L. Geyer, MD, Shreekant V. Parasuraman, BPharm, PhD, Ruben A. Mesa, MD

Blood (2017) 130 (Supplement 1): 1637.

https://doi.org/10.1182/blood.V130.Suppl_1.1637.1637

Published: 2017

NARROW

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Direct and Indirect Costs of Patients with Myeloproliferative Neoplasm Diseases

Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study)

Disability Associated with Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States

Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the Reveal Prospective, Observational Study

Thrombosis and Risk of Mortality in Newly Diagnosed High-Risk Polycythemia Vera: An Analysis of the Medicare Claims Database in the United States

Thrombotic Events and Mortality Risk in Patients Newly Diagnosed with Intermediate- to High-Risk Essential Thrombocythemia in the United States

Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Disease Progression, Hospital Readmissions, and Clinical Outcomes of Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Chart Review

Elevated White Blood Cell Levels and Thrombotic Events in Patients with Polycythemia Vera: A Real-World Analysis of Veterans Health Administration Data

Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United States

Impact of Myeloproliferative Neoplasms on Patients' Employment and Income: Findings from the Living with MPN Survey

Real-World Patterns of First-Line Hydroxyurea Treatment Among Patients with Essential Thrombocythemia in US Community Oncology Practices

Characteristics of 809 Patients with Essential Thrombocythemia in Real-World Clinical Practice: A Chart Review Study in the United States

Role of Symptom Burden in Disability Leave Among Patients with Myeloproliferative Neoplasms (MPNs): Findings from the Living with MPN Patient Survey

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only